Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$1.15 - $1.48 $148,607 - $191,251
129,224 Added 17.03%
888,167 $1.14 Million
Q4 2023

Feb 13, 2024

BUY
$1.22 - $1.62 $293,380 - $389,571
240,476 Added 46.38%
758,943 $1.03 Million
Q3 2023

Nov 14, 2023

SELL
$0.98 - $1.62 $43,218 - $71,442
-44,100 Reduced 7.84%
518,467 $798,000
Q2 2023

Aug 11, 2023

SELL
$0.58 - $1.31 $6,264 - $14,148
-10,800 Reduced 1.88%
562,567 $534,000
Q1 2023

May 12, 2023

SELL
$0.76 - $1.82 $219,564 - $525,798
-288,900 Reduced 33.5%
573,367 $573,000
Q4 2022

Feb 13, 2023

SELL
$0.64 - $0.91 $230,319 - $327,485
-359,874 Reduced 29.45%
862,267 $615,000
Q3 2022

Nov 14, 2022

SELL
$0.68 - $1.11 $226,888 - $370,361
-333,659 Reduced 21.45%
1,222,141 $785,000
Q2 2022

Aug 12, 2022

BUY
$0.75 - $1.33 $503,025 - $892,031
670,700 Added 75.78%
1,555,800 $1.43 Million
Q1 2022

May 13, 2022

BUY
$1.29 - $4.04 $727,689 - $2.28 Million
564,100 Added 175.73%
885,100 $1.17 Million
Q4 2021

Feb 11, 2022

SELL
$3.45 - $6.05 $290,145 - $508,805
-84,100 Reduced 20.76%
321,000 $1.24 Million
Q3 2021

Nov 12, 2021

BUY
$5.53 - $9.28 $1.75 Million - $2.93 Million
316,100 Added 355.17%
405,100 $2.26 Million
Q2 2021

Aug 13, 2021

BUY
$7.84 - $12.6 $697,760 - $1.12 Million
89,000 New
89,000 $791,000
Q1 2021

May 13, 2021

SELL
$10.54 - $19.3 $427,923 - $783,580
-40,600 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$12.79 - $17.1 $323,587 - $432,630
25,300 Added 165.36%
40,600 $566,000
Q3 2020

Nov 13, 2020

SELL
$12.99 - $19.41 $275,777 - $412,074
-21,230 Reduced 58.12%
15,300 $199,000
Q2 2020

Aug 13, 2020

BUY
$12.19 - $22.96 $445,300 - $838,728
36,530 New
36,530 $637,000
Q3 2019

Nov 13, 2019

SELL
$14.12 - $23.44 $224,508 - $372,696
-15,900 Closed
0 $0
Q2 2019

Aug 12, 2019

BUY
$13.21 - $27.29 $210,039 - $433,911
15,900 New
15,900 $259,000

Others Institutions Holding AVRO

# of Institutions
1
Shares Held
559K
Call Options Held
0
Put Options Held
0

About AVROBIO, Inc.


  • Ticker AVRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,773,900
  • Description
  • AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...
More about AVRO
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.